Coherus Oncology, Inc. Total Assets

Quick Answer

Coherus Oncology, Inc. reported Total Assets of $258.34 million for the year ending 2025.

  • Coherus Oncology, Inc. showed a decrease of -42.4% in Total Assets from 2024 to 2025.
  • This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q3 2014: $129.18 million | Q1 2015: $153.15 million | Q2 2015: $249.55 million | Q3 2015: $202.31 million | Q1 2016: $226.24 million | Q2 2016: $251.10 million | Q3 2016: $192.36 million | Q1 2017: $227.50 million | Q2 2017: $172.25 million | Q3 2017: $189.76 million | Q1 2018: $128.46 million | Q2 2018: $188.31 million | Q3 2018: $141.46 million | Q1 2019: $186.12 million | Q2 2019: $240.46 million | Q3 2019: $327.38 million | Q1 2020: $466.54 million | Q2 2020: $756.61 million | Q3 2020: $803.73 million | Q1 2021: $693.30 million | Q2 2021: $739.54 million | Q3 2021: $741.73 million | Q1 2022: $593.39 million | Q2 2022: $546.00 million | Q3 2022: $550.91 million | Q1 2023: $402.43 million | Q2 2023: $469.59 million | Q3 2023: $583.78 million | Q1 2024: $763.55 million | Q2 2024: $674.86 million | Q3 2024: $505.00 million | Q1 2025: $371.07 million | Q2 2025: $439.46 million | Q3 2025: $516.52 million.
  • Over the full 13 years of available data (2013 to 2025), Coherus Oncology, Inc.'s Total Assets has grown by 444.5%.
  • Historical annual values: Fiscal year 2025: $258.34 million | Fiscal year 2024: $448.53 million | Fiscal year 2023: $629.60 million | Fiscal year 2022: $480.85 million | Fiscal year 2021: $679.33 million | Fiscal year 2020: $841.65 million | Fiscal year 2019: $408.93 million | Fiscal year 2018: $99.47 million | Fiscal year 2017: $162.61 million | Fiscal year 2016: $178.49 million | Fiscal year 2015: $212.38 million | Fiscal year 2014: $187.22 million | Fiscal year 2013: $47.45 million.
  • Data sourced from SEC EDGAR public filings as of August 4, 2026.

Last verified: